Enliven Therapeutics’ (ELVN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $37.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an outperform rating and a $32.00 price target for the company. Baird R W upgraded shares of Enliven Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Stock Up 7.9 %

Enliven Therapeutics stock opened at $27.53 on Tuesday. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -14.26 and a beta of 1.09. The business has a 50-day simple moving average of $23.21 and a 200 day simple moving average of $21.97. Enliven Therapeutics has a 52 week low of $9.80 and a 52 week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, research analysts anticipate that Enliven Therapeutics will post -1.98 earnings per share for the current year.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $24.27, for a total value of $103,147.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $26.70, for a total transaction of $320,400.00. Following the sale, the insider now owns 1,093,035 shares of the company’s stock, valued at approximately $29,184,034.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,376 shares of company stock worth $3,169,342 in the last quarter. 29.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after buying an additional 3,189 shares during the period. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics during the 1st quarter valued at $167,000. SG Americas Securities LLC purchased a new stake in Enliven Therapeutics during the 3rd quarter valued at $256,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics in the 2nd quarter worth $322,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.